Missouri § 208.184 Rare diseases, advisory council — sickle cell disease and MO HealthNet beneficiaries, annual evaluation and review — report.

Missouri Statutes

§ 208.184 — Rare diseases, advisory council — sickle cell disease and MO HealthNet beneficiaries, annual evaluation and review — report.

Missouri § 208.184

Title XIIPUBLIC HEALTH AND WELFARE

Ch. 208Old Age Assistance, Aid to Dependent Children and General Relief

This text of Missouri § 208.184 (Rare diseases, advisory council — sickle cell disease and MO HealthNet beneficiaries, annual evaluation and review — report.) is published on Counsel Stack Legal Research, covering Missouri primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Mo. Rev. Stat. § 208.184 (2026).

Text

1. During at least one regularly scheduled meeting each calendar year, the advisory council on rare diseases and personalized medicine established in section 208.183 shall dedicate time to:

(1)Discuss and evaluate whether the available covered medications, treatments, and services are adequate to meet the needs of MO HealthNet beneficiaries with a diagnosis of sickle cell disease;

(2)Review information on treatments for sickle cell disease in late-stage studies that show promise in peer-reviewed medical literature; and

(3)Review the importance of provider education on the disproportionate impact of sickle cell disease on specific minority populations. 2. After each annual review of the issues described under subsection 1 of this section, staff members of the MO HealthNet divisi

Free access — add to your briefcase to read the full text and ask questions with AI

1. During at least one regularly scheduled meeting each calendar year, the advisory council on rare diseases and personalized medicine established in section 208.183 shall dedicate time to:

(1) Discuss and evaluate whether the available covered medications, treatments, and services are adequate to meet the needs of MO HealthNet beneficiaries with a diagnosis of sickle cell disease;

(2) Review information on treatments for sickle cell disease in late-stage studies that show promise in peer-reviewed medical literature; and

(3) Review the importance of provider education on the disproportionate impact of sickle cell disease on specific minority populations.

2. After each annual review of the issues described under subsection 1 of this section, staff members of the MO HealthNet division, under the guidance of the advisory council on rare diseases and personalized medicine, may develop their own report on the issues described under subsection 1 of this section to be made available to the public or may solicit expert testimony or input on such issues, which may be compiled and posted on the website of the MO HealthNet division.